Drug Profile
Trevogrumab - Regeneron Pharmaceuticals
Alternative Names: GDF8; REGN-1033; SAR-391786Latest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; Sanofi
- Class Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Sarcopenia
- No development reported Musculoskeletal disorders; Osteoporosis
Most Recent Events
- 13 Mar 2024 Phase-II clinical trials in Obesity (Combination therapy) in USA (SC)
- 13 Mar 2024 Phase-II clinical trials in Obesity (Monotherapy) in USA (SC) (NCT06299098)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Osteoporosis in USA (Parenteral)